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Hypermethylated genes are emerging as some of the most
promising, practical and powerful biomarkers for breast
cancer detection and perhaps even of risk assessment. We
have assembled a panel of methylated gene detection
markers and tested them by Quantitative Multiplex Meth-
ylation-Specific PCR (QM-MSP) in breast cancer. Here we
two pilot studies: 1) detection of cancer in DNA from
spontaneous nipple discharge (SND) and 2) assessing
risk, and its possible reduction in contralateral breast tis-
sue of women undergoing treatment with aromatase
inhibitors.
SND is most frequently caused by intraductal papilloma
(66%), but in a minority of women (~10%) it is caused by
ductal carcinoma in situ (DCIS). Therefore essentially all
women with SND are screened for breast cancer. All the
current methods used for screening exhibit low sensitivity
and specificity for detection of cancer. Mammary endos-
copy (ductoscopy) appears to improve localization of
lesions in patients with SND and allows retrieval of intra-
ductal cells for diagnostic purposes. Development of a
non-surgical method to reliably diagnose cancer would
offer the possibility of diagnosis without surgery for the
majority of women with SND who have a very low likeli-
hood of significant neoplasia. Further, a reliable diagnos-
tic test of intraductal pathology will enable in-situ
ablation of benign lesions with either endoscopic tech-
niques or the intraductal administration of anti-neoplas-
tic agent. In a pilot study we investigated whether
quantitative assessment of gene promoter hypermethyla-
tion could enhance detection of breast cancer in women
with spontaneous nipple discharge (SND) when used in
conjunction with ductoscopy. Ducts with significant visu-
alized lesions were surgically resected (36 ducts in 33
women) and those with minimal findings were not (28
ducts in 16 women). QM-MSP data of DNA from cells in
ductoscopic washings were compared to ductoscopy find-
ings, cytology, and tissue histology. Cells from ducts with
significant ductoscopic findings had higher levels of
methylation while cells found in ducts with minimal find-
ings had minimal methylation; methylation was higher in
cells from ducts with malignant lesions compared to low
methylation in ducts bearing benign lesions such as pap-
illoma.  RASSF1A, TWIST1,  and  HIN1  cumulative gene
methylation accurately distinguished cells washed from
ducts with cancerous vs. benign lesions (100% sensitivity,
72% specificity and AUC of 0.91 according to ROC anal-
yses). Using QM-MSP the positive predictive value of duc-
toscopy more than doubled because QM-MSP has three-
fold higher sensitivity than cytology in evaluation of duc-
tal cells. This study demonstrates the potential benefit of
targeting surgical ductal excision to ducts that have both
high methylation and significant abnormalities on duc-
toscopy. Future large-scale studies to validate this
approach are needed.
Women with a history of breast cancer are at increased risk
to develop a contralateral breast (CLB) cancer. Since gene
methylation occurs early in tumorigenesis, and is fre-
quently higher in normal tissues adjacent to a breast
tumor, we hypothesized that women with a prior breast
cancer would harbor higher levels of methylated genes in
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the CLB and that treatment with anastrozole, an aro-
matase inhibitor that reduces the risk of CLB cancer,
would decrease methylation levels. We conducted a pro-
spective, single-arm study in 54 postmenopausal women
with hormone receptor-positive stage 0–III breast cancer
who had completed local therapy, had an intact CLB, and
would receive anastrozole as their sole adjuvant therapy.
Of those, 33 women underwent an optional CLB biopsy
both at baseline and 6 months after initiating Anastro-
zole. At baseline, 84% of paired samples had measurable
cumulative methylation of the 6 gene panel; TWIST1,
RASSF1A, and RAR  were most frequently methylated.
After 6 months of anastrozole, we observed significant
decreases in methylation for TWIST1,  RASSF1A, and
RAR, among patients with methylation identified at
baseline. These preliminary findings emphasize the need
for prospective evaluation of the relationship between
changes in methylation and incidence of breast cancer in
high-risk women.